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ABSTRACT
PGE2, produced in the lung during infection with mi-
crobes such as Klebsiella pneumoniae, inhibits alveolar
macrophage (AM) antimicrobial functions by preventing
H2O2 production by NADPH oxidase (NADPHox). Acti-
vation of the NADPHox complex is poorly understood in
AMs, although in neutrophils it is known to be mediated
by kinases including PI3K/Akt, protein kinase C (PKC) ,
p21-activated protein kinase (PAK), casein kinase 2
(CK2), and MAPKs. The p40phox cytosolic subunit of
NADPHox has been recently recognized to function as
a carrier protein for other subunits and a positive regu-
lator of oxidase activation, a role previously considered
unique to another subunit, p47phox. The regulation of
p40phox remains poorly understood, and the effect of
PGE2 on its activation is completely undefined. We ad-
dressed these issues in rat AMs activated with IgG-op-
sonized K. pneumoniae. The kinetics of kinase activa-
tion and the consequences of kinase inhibition and si-
lencing revealed a critical role for a PKC-PAK-class I
PI3K/Akt1 cascade in the regulation of p40phox activa-
tion upon bacterial challenge in AMs; PKC, ERK, and
CK2 were not involved. PGE2 inhibited the activation of
p40phox, and its effects were mediated by protein ki-
nase A type II, were independent of interactions with
anchoring proteins, and were directed at the distal
class I PI3K/Akt1 activation step. Defining the kinases
that control AM p40phox activation and that are the
targets for inhibition by PGE2 provides new insights into
immunoregulation in the infected lung. J. Leukoc. Biol.
92: 219–231; 2012.
Introduction
Pneumonia is the leading cause of infectious death in the
United States [1], and World Health Organization data indi-
cate that respiratory infections have a greater global impact
than any other category of disease [2]. Resistance to antimi-
crobial agents is a major challenge in the treatment of pneu-
monia, exemplified by the emergence of multidrug-resistant
gram-negative bacteria such as Klebsiella pneumoniae [3]. A bet-
ter understanding of host innate immune defenses against
pneumonia-causing pathogens is an important step in develop-
ing novel preventive and therapeutic strategies. Alveolar mac-
rophages (AMs) are the resident innate immune cells of the
distal lung [4]. One pivotal means by which they eliminate
microbes is the generation of reactive oxygen intermediates
(ROIs) [5, 6], primarily via the actions of the phagocyte oxi-
dase NADPH oxidase (NADPHox).
NADPHox [7] is a multisubunit complex comprising 1) a
catalytic core consisting of gp91phox and p22phox (cyto-
chrome b558), localized at the membrane, along with the reg-
ulator Rap1a, a Ras-related GTP-binding protein, and 2) cyto-
solic subunits p47phox, p67phox, and p40phox and a small
GTP-binding protein, either Rac1 or Rac2. Moreover, peroxire-
doxin 6, a dual-function enzyme that includes a phospholipase
A2 activity, has been recently shown to facilitate the assembly
and the activation of the oxidase complex [8]. NADPHox acti-
vation requires the phosphorylation of cytosolic subunits,
which results in their recruitment to the catalytic core at the
membrane [9]. The classic paradigm for NADPHox activation
recognized p47phox as the primary initiator of cytosolic sub-
unit translocation responsible for carrying p40phox and
p67phox subunits to the membrane [10–14]. However, recent
studies have revealed an essential role for p40phox in
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NADPHox activation [15–19]. It has been acknowledged that
p40phox has an independent carrier role, and both p47phox
and p40phox are now thought to be required for full and sta-
ble activation of NADPHox [20–22].
The activation of NADPHox stimulated by ligation of the
opsonic Fc receptor (FcR) for IgG has been well studied in
neutrophils. In this model, numerous kinases have been dem-
onstrated to mediate cytosolic subunit phosphorylation, includ-
ing PI3K and its downstream partner Akt, protein kinase C
(PKC) , p21-activated protein kinase (PAK), casein kinase 2
(CK2), and ERK, and p38 forms of MAPKs [12, 22–24]. The
activation of each of these kinases is controlled by its own
phosphorylation level and can be opposed by a variety of phos-
phatases. Despite their importance in pulmonary antimicrobial
defense, much less is known about NADPHox activation in
primary AMs than in either peripheral blood neutrophils or
macrophage cell lines.
During infection of the distal lung and other sites, PGE2, a
bioactive lipid mediator derived from the cyclooxygenase me-
tabolism of arachidonic acid, is generated in large quantities
by both macrophages and neighboring epithelial cells [25–27].
Although PGE2 is often viewed as a pro-inflammatory media-
tor, its effects on phagocytes are largely suppressive and in-
clude inhibition of FcR-mediated microbial killing and
NADPHox activity [28]. These suppressive actions may help to
promote resolution of tissue inflammation once infection has
been contained, but enhanced production of PGE2 could im-
pair innate immunity. Indeed, excessive generation of PGE2
has been implicated in immunosuppressive states including
bone marrow transplantation [29–31], cancer [32], aging
[33], malnutrition [34], and cystic fibrosis [35]. These sup-
pressive actions on macrophages, including AMs, are mediated
by ligation of E prostanoid (EP) receptors 2 and 4, which are
coupled to a stimulatory G protein -subunit that activates ad-
enylyl cyclase to catalyze the formation of cAMP [36–39]. The
main target of this second messenger is the effector protein
kinase A (PKA), a holoenzyme composed of two catalytic (C)
subunits that are held in an inactive conformation by a dimer
of regulatory (R) subunits of either RI or RII type [40]. The
holoenzyme is activated when cAMP binds to the R subunits,
releasing the active C subunits [40]. A-kinase anchoring pro-
teins (AKAPs) are a family of large scaffold proteins that can
organize and localize PKA and its signaling partners at specific
subcellular sites [40].
In view of the recently recognized importance of p40phox
in the regulation of NADPHox and the paucity of knowledge
regarding its regulation, the first goal of this study was to char-
acterize the kinase network responsible for FcR-mediated acti-
vation of p40phox in AMs. This information then provided a
framework for determining the regulatory events targeted by
PGE2 to effect inhibition of FcR-mediated p40phox activa-
tion. We used AM challenged with IgG-opsonized K. pneu-
moniae, because 1) this represents a biologically relevant stimu-
lus, 2) the FcR signaling pathway has been extensively charac-
terized in neutrophils, and 3) we have previously observed
inhibition of this process by PGE2 in AMs [28]. This work pro-
vides new mechanistic insights and may reveal new opportuni-




Pathogen-free 125- to 150-g female Wistar rats from Charles River Laborato-
ries (Portage, MI, USA) were used. Animals were treated according to NIH
guidelines for the use of experimental animals with the approval of the
University of Michigan Committee for the Use and Care of Animals.
Reagents
RPMI 1640 was purchased from Gibco-Invitrogen (Carlsbad, CA, USA).
Protein A-Sepharose beads were purchased from GE Healthcare (Piscat-
away, NJ, USA). PGE2 from Cayman Chemical (Ann Arbor, MI, USA) was
dissolved in DMSO and stored under N2 at 80°C. Rabbit polyclonal Abs
against phospho-p40phox (Thr154), p40phox, p47phox, phospho-PKC
(Thr507), and PKC, as well as mouse polyclonal Ab against PAK, were
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse polyclonal
anti-gp-91phox was from BD Biosciences (San Jose, CA, USA). Mouse poly-
clonal Abs against phospho-Akt (Ser473) and phospho-ERK (Thr202/
Tyr204), and rabbit polyclonal Abs against Akt, Akt1, phospho-p38 MAPK
(Thr180/Tyr182), phospho-PAK1 (Thr423)/PAK2 (Thr402), and ERK were
from Cell Signaling Technology (Danvers, MA, USA). Mouse monoclonal
Ab against -actin was from Sigma-Aldrich (St. Louis, MO, USA). PKA-RII-
selective activator N6-mono-t-butylcarbamoyladenosine-3=,5=-cyclic mono-
phosphate (6-MBC-cAMP), PKA RI-selective inhibitor 8-chloroadenosine-
3=,5=-cyclic monophosphorothioate, Rp-isomer (Rp-8-Cl-cAMPS) and PKA
RII-selective inhibitor 8-piperidinoadenosine-3=,5=-cyclic monophosphoro-
thioate, Rp-isomer (Rp-8-PIP-cAMPS) were purchased from Biolog Life Sci-
ence Institute (Howard, CA, USA). The PKA-RII/AKAP disruptor peptide
Ht31, and its corresponding control peptide Ht31P, were obtained from
Promega (Madison, WI, USA). Kinase inhibitors rottlerin (PKC), LY29004
(PI3K), PAK18 (PAK), Akti-VIII (Akt), Ro-32-0432 (PKC), U0126 (ERK1/
2), SB203580 (p38 MAPK), phosphoinositide-dependent kinase (PDK) 1
inhibitor II (PDK1), bpV(bipy) [phosphatase and tensin homolog deleted
on chromosome 10 (PTEN)], and 4,5,6,7-tetrabromobenzotriazole (TBB)
and (E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid (TBCA) (CK2) were pur-
chased from Calbiochem (San Diego, CA, USA). Specific class I PI3K inhibi-
tors IC87114 (p110 catalytic subunit) and GDC-0941 (p110 catalytic sub-
unit) were obtained from Selleck Chemicals (Houston, TX, USA). AS605240
(p110 catalytic subunit) and TGX-221 (p110 catalytic subunit) were pur-
chased from Cayman Chemical. Compounds requiring reconstitution were
dissolved in either PBS or DMSO. Required dilutions of all compounds
were prepared immediately before use, and equivalent quantities of vehicle
were added to the appropriate controls. DMSO at the concentrations used
(0.0001–1%) had no direct effect on H2O2 generation.
Cell isolation and culture
Resident AMs from rats were obtained by lung lavage, as described previ-
ously [28] and were resuspended in RPMI 1640 to a final concentration of
1–3  106 cells/ml. Cells were allowed to adhere to tissue culture-treated
plates for 1 h (37°C, 5% CO2), resulting in 99% of adherent cells identi-
fied as macrophages by use of modified Wright-Giemsa stain (Diff-Quick)
from American Scientific Products (McGraw Park, IL, USA). Cells were cul-
tured overnight in RPMI 1640 containing 5% FBS. The following day, me-
dium was removed to remove nonadherent cells and replaced by PBS for
treatment. For Amplex UltraRed experiments, RPMI 1640 without phenol
red was used.
Cell treatments
AMs were pretreated with or without kinase inhibitors for 30 min and with
or without PGE2 or cAMP analog for 10 min and then were challenged
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with IgG-opsonized K. pneumoniae (IgG-K. pneumoniae) [multiple of infec-
tion (MOI) 50:1] for time intervals ranging from 1 to 15 min (Western
blot for kinase phosphorylation) or 60 min (Amplex UltraRed for H2O2
production). Immune serum, source of the bacteria, and method for op-
sonization were as described previously [41]. For some Amplex experi-
ments, cells were also treated with 50:1 unopsonized K. pneumoniae (K.
pneumoniae).
H2O2 detection
AMs were plated in 96-well dishes at 5  105 cells/well. To determine
H2O2 secretion from AMs, we adapted our previous colorimetric assay [28]
to the fluorimetric assay using the Amplex UltraRed reagent (Molecular
Probes, Eugene, OR, USA) according to the manufacturer’s instructions
with some modifications. In brief, AMs were incubated for 1 h directly with
50 l of PBS containing 200 M Amplex UltraRed reagent and 20 U/ml
HRP in the presence or absence of IgG-K. pneumoniae. To assess the effects
of kinase activation and PGE2 signaling on H2O2 production, AMs were
pretreated with compounds as described above before challenge with
IgG-K. pneumoniae. For some Amplex experiments, cells were also treated
with unopsonized K. pneumoniae. Values from a given condition in each
independent experiment were taken as the mean of 5 replicates. The stim-
ulated increment in H2O2 was calculated by subtracting the mean value of
5 untreated replicates from the raw value for each of the 5 replicates corre-
sponding to a single condition. Data were expressed as a percentage of the
stimulated increment in H2O2 or as indicated otherwise in figure legends.
Consistent with a prior report from our laboratory [28], H2O2 concentra-
tions in medium of IgG-K. pneumoniae-treated AMs (0.32 M) were ap-
proximately twice those measured in untreated cells (0.16 M).
Western blotting
AMs (3106) were plated in 6-well tissue culture dishes and incubated in
the presence or absence of compounds of interest and IgG-K. pneumoniae,
after which they were lysed in ice-cold PBS containing 1% Nonidet P-40,
0.5% sodium deoxycholate, 0.1% SDS, 1 mM PMSF, protease inhibitor
cocktail (1 tablet/5 ml) from Roche Diagnostics (Indianapolis, IN, USA)
and phosphatase inhibitor cocktail set I and II (1/100) from Calbiochem.
Protein concentrations were determined by the Bio-Rad DC protein assay
(modified Lowry protein assay) from Bio-Rad Laboratories (Hercules, CA,
USA). Samples containing 40 g of protein were separated by SDS-PAGE
using 8% gels and then transferred overnight to nitrocellulose membranes.
After blocking with 4% BSA, membranes were probed overnight with commer-
cially available Abs (titer of 1:1000, except for the Ab against -actin: titer of
1:10,000) directed against phospho-specific or total NADPHox components or
kinases. The phospho-specific Abs used recognized residues whose phosphory-
lation is known to be associated with activation [15, 42–45]. After incubation
with peroxidase-conjugated goat anti-rabbit (or anti-mouse) secondary Ab
(titer of 1:10,000) from Cell Signaling Technology, film was developed using
ECL detection from Amersham Biosciences (Piscataway, NJ, USA). Relative
band densities were determined by densitometric analysis using NIH ImageJ
software, and relative band densities for experimental conditions were ex-
pressed as described in figure legends. In all instances, density values of bands
were corrected by subtraction of the background values.
Cell fractionation and Western blotting
AMs (4106) were plated in 6-well tissue culture dishes and pretreated for
10 min with PGE2 or cAMP analog specific for PKA-RII. After this, AMs
were lysed by sonication in ice-cold buffer consisting of 25 mM Tris-HCl,
pH 7.4, 150 mM NaCl, and 5 mM EDTA followed by ultracentrifugation at
100,000 g for 1 h at 4°C. The membrane (insoluble) fraction was washed
and subjected to another ultracentrifugation step as described above. The
resultant pellet was resuspended in lysis buffer and sonicated. Protein con-
centrations were determined as described above. Samples containing pro-
tein were subjected to immunoblot analysis as described above by incubat-
ing overnight with anti-phospho-p40phox, anti-p47phox (1:1000 dilution;
Santa Cruz Biotechnology) or anti-gp91phox (1:500; BD Biosciences), fol-
lowed by peroxidase conjugated anti-rabbit or anti-mouse secondary Ab as
described above. The results were expressed as normalized phospho-
p40phox/total gp91phox.
Immunoprecipitation and Western blotting
For p40phox immunoprecipitation, macrophage monolayers were washed
once and lysed in the lysis buffer described in the Western blotting section.
In these experiments, the AMs were pretreated for 10 min with or without
1 M PGE2 followed by the addition of 50:1 IgG-K. pneumoniae for 15 min.
Total protein concentrations were determined as described above. Lysates
were incubated overnight at 4°C with anti-p40phox (1:80; Santa Cruz Bio-
technology). Protein A-Sepharose was added to each sample and incubated
for 3 h with rotation at 4°C. The beads were washed briefly three times
with lysis buffer without Triton X-100, and proteins were separated on 8%
SDS-PAGE gels. The entire volume recovered after boiling the beads was
loaded onto the gel, and the proteins were transferred to nitrocellulose
membranes overnight. Those membranes were then incubated with Abs
against Akt1 and p40phox.
RNA interference
RNA interference was performed according to a protocol provided by
Dharmacon (Lafayette, CO, USA). Rat AMs were transfected using lipo-
fectamine RNAiMax reagent from Invitrogen with 100 nM nontargeting
SMARTpool control or specific ON-TARGET SMARTpool Akt1 (Akt1)
small interfering RNA (siRNA) from Dharmacon. After 48 h of transfec-
tion, AMs were challenged with IgG-K. pneumoniae for 15 min (Western
blot for kinase phosphorylation) or 60 min (Amplex UltraRed for H2O2
production).
Statistical analysis
The data are presented as means  SE from three or more independent
experiments and were analyzed with the Prism 5.0 statistical program from
GraphPad Software (La Jolla, CA). The group means for different treat-
ments were compared by ANOVA, followed by Bonferroni analysis when
significant differences were identified. Statistical significance was set at P 
0.05.
RESULTS
Kinases PKC, PI3K/Akt, and PAK mediate H2O2
production and p40phox activation in AMs challenged
with IgG-K. pneumoniae
We sought to determine whether kinases known to participate
in the activation of NADPHox in neutrophils or monocytes
[12, 23, 24] also participate in the activation of the respiratory
burst as well as of p40phox in AMs. Relatively specific kinase
inhibitors were used at concentration ranges utilized in previ-
ous reports. The stimulated increment in H2O2 was dose de-
pendently decreased by the PKC inhibitor rottlerin (Fig. 1A),
the PI3K inhibitor LY29004 (Fig. 1A), the PAK inhibitor pep-
tide PAK18 (Fig. 1B), the Akt inhibitor Akti-VIII (Fig. 1B), the
ERK inhibitor U0126 (Fig. 1C), and the p38 MAPK inhibitor
SB203580 (not shown). As seen in Fig. 1A, H2O2 levels de-
creased below that found in uninfected cells at doses 6 M
rottlerin or 1.5 M LY29004. In contrast to these data sup-
porting a role for PKC, PAK, PI3K/Akt, ERK, and p38 MAPK
in FcR-triggered production of AM H2O2, inhibitor studies
failed to support a role for PKC or CK2 (Fig. 1C), because
neither Ro-32-0432 nor TBB [or TBCA (not shown)], respec-
tively, was able to significantly decrease H2O2 production in-
duced by IgG-K. pneumoniae. Only class I isoforms produce
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phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which inter-
acts with the phox homology (PX) domain of p47phox and
p40phox, yet LY29004 inhibits all 3 classes of PI3K. To deter-
mine the specific role of PI3K class I, known to be expressed
in AMs [46, 47], in regulating H2O2 production, we per-
formed additional experiments with the p110 catalytic sub-
unit-specific inhibitor GDC-0941, the p110 subunit-specific
inhibitor TGX-221, the p110 subunit-specific inhibitor
AS605240, and the p110 subunit-specific inhibitor IC87114.
We observed that all these inhibitors were effective (not
shown), suggesting redundant roles for all of these class I PI3K
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Figure 1. Activation of the kinases PKC, PI3K/Akt, and PAK mediates IgG-K. pneumoniae stimulation of H2O2 generation and p40phox activation.
AMs were preincubated for 30 min with the specified doses of (A) PKC inhibitor rottlerin and PI3K inhibitor LY29004, (B) PAK inhibitor PAK18
and Akt inhibitor Akti-VIII, and (C) the ERK inhibitor U0126, the PKC inhibitor Ro-32-0432, and the CK2 inhibitor TBB. They were then chal-
lenged with IgG-K. pneumoniae (MOI 50:1) for 1 h. The H2O2 concentration in medium was determined fluorometrically. (D–G) Cells were pre-
treated for 30 min with the inhibitors of PKC (6 M), PI3K (1.5 M), PAK (100 M), and Akt (50 M) (D), ERK (5 M) (E), PKC (15 nM)
(F), and p38MAPK (10 M) (G) noted above or in the materials and methods and then were stimulated with 50:1 opsonized K. pneumoniae for 15
min. Cells were lysed, and proteins were subjected to immunoblot analysis of p-p40phox. Data are expressed as the percentage of stimulated incre-
ment in H2O2 (A, B, and C) and p40phox phosphorylation after quantification of blot band densities by densitometry (D and E) in cells stimu-
lated with IgG-K. pneumoniae alone (black) and represent the mean  se from at least 3 independent experiments (A–E) or as a representative
blot of 2 experiments (F and G). #P  0.05 versus untreated cells; *P  0.05 versus IgG-K. pneumoniae alone. p, phospho; i, inhibitor.
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that PKC, PI3K/Akt, PAK, p38 MAPK, and ERK mediate acti-
vation of p40phox in parallel with their role in H2O2 genera-
tion, we tested the effects of these same specific kinase inhibi-
tors on p40phox phosphorylation on Thr154. Phosphorylation
of p40phox on this residue is associated with its translocation
and activation [15]. As seen in Fig. 1D, phosphorylation of
p40phox in stimulated AMs was also markedly inhibited by
optimal doses of the inhibitors of PKC, PI3K/Akt, and PAK;
in contrast, the ERK inhibitor (Fig. 1E), the PKC inhibitor
(Fig. 1F), and the p38 MAPK inhibitor (Fig. 1G) had no effect
on phosphorylation of p40phox.
Phosphorylation of p40phox in AMs occurred in a time-de-
pendent manner, being evident within 5 min of addition of
IgG-K. pneumoniae and reaching a plateau at 10–15 min
(Fig. 2A). We next determined the kinetics of activation of
those kinases identified above as being involved in H2O2 regu-
lation in stimulated AMs. PKC exhibited some degree of basal
phosphorylation even in untreated cells; this phenomenon of
basal PKC activation in AMs has been recognized previously
[48]. However, upon stimulation, its degree of phosphoryla-
tion rapidly increased and peaked within 1 min (Fig. 2B),
clearly preceding the phosphorylation of p40phox itself. Phos-
phorylation of both PAK (Fig. 2C) and Akt (Fig. 2D) occurred
with kinetics corresponding to the activation of p40phox. In
contrast, phosphorylation of ERK (Fig. 2E) and CK2 (not
shown) was not seen until 10 min postchallenge. These kinetic
data suggest that PKC may be an early participant in the acti-
vation of p40phox in our system, PAK and PI3K/Akt might be
subsequent participants, and ERK and CK2 are unlikely to be
critical contributors.
Hierarchy of kinases mediating p40phox activation
and subsequent H2O2 production
PKC, PI3K/Akt, and PAK all participate in p40phox activa-
tion in AMs, but PKC appears to be the kinase activated first
in response to infection. To determine the functional relation-
ships among participating kinases, we tested the effects of spe-
cific kinase inhibitors on the phosphorylation of other kinases.
The PKC inhibitor abrogated activation of PAK (Fig. 3A), Akt
(Fig. 3B), and p38 MAPK (not shown). The PAK inhibitor de-
creased phosphorylation of both Akt (Fig. 3C) and ERK (Fig.
3D). In contrast, the PI3K inhibitor had no effect on phos-
phorylation of either PKC (Fig. 3E), ERK (Fig. 3F), or p38
MAPK (not shown). Taken together, these data define a tem-
poral and functional hierarchy in AMs (depicted in the
scheme in Fig. 7, left) in which PKC activation controls the
subsequent activation of 1) PAK, which in turn mediates acti-
vation of both PI3K/Akt/p40phox and ERK as well as 2) p38
MAPKs; although these MAPKs participate in the regulation of
H2O2 generation, they apparently do so in a matter indepen-
dent of effects on p40phox activation. This kinase cascade ulti-
mately results in the activation of NADPHox to produce H2O2.
In contrast, PKC and CK2 do not participate in FcR-depen-
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Figure 2. Kinetics of activation of p40phox
and various kinases after AM stimulation with
IgG-K. pneumoniae. AMs were exposed to 50:1
IgG-K. pneumoniae for 1, 5, 10, and 15 min.
Cells were lysed, proteins were subjected to
SDS-PAGE, and the membranes were probed
for (A) p-p40 phox, (B) p-PKC, (C) p-PAK,
(D) p-Akt, and (E) p-ERK. Blots were ana-
lyzed by densitometry, and band densities are
presented as the mean  se from at least 3
independent experiments. Data are expressed
as the percentage of kinase phosphorylation
in cells stimulated with IgG-K. pneumoniae for
15 min (black). *P  0.05 versus untreated
cells. p, phospho.
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Unanchored PKA type II mediates PGE2 inhibition of
H2O2 production and p40phox activation
We have previously reported that PGE2 and cAMP signaling
inhibited the activation of NADPHox in AMs, with concomi-
tant inhibition of p47phox [28]. However, to our knowledge
regulation of p40phox by cAMP/PGE2 has not previously been
explored in any cell type. Characterizing the network of ki-
nases involved in activating p40phox upon IgG-K. pneumoniae
challenge provided a basis for investigating their possible inhi-
bition by PGE2 and the cAMP effector PKA.
We assessed the specific role of individual PKA isoforms in
mediating the PGE2 inhibition of IgG-K. pneumoniae-induced
H2O2 generation. To accomplish this, we pretreated AMs for
30 min with various doses of specific inhibitors against PKA-RI
(Rp-8-Cl-cAMPS) and PKA-RII (Rp-8-PIP-cAMPS) before PGE2
addition, challenged with IgG-K. pneumoniae, and monitored
H2O2 production. We previously showed that the inhibitory
effects of PGE2 on H2O2 triggered by FcR ligation were dose-
dependent over the range from 10 nM to 1 M [28], and the
maximally effective dose of 1 M PGE2 was used for these ex-
periments. Only the PKA-RII inhibitor dose-dependently and
significantly prevented the inhibitory effects of PGE2 (Fig. 4A),
implicating PKA type II as an endogenous mediator of the
suppressive effects of PGE2. Moreover, when added exoge-
nously, a PKA-RII-selective agonist (6-MBC-cAMP) mimicked
the inhibitory effects of PGE2 (Fig. 4B), with a dose of 160 M
completely abrogating the H2O2 production elicited by IgG-K.
pneumoniae challenge. At this same dose, the specific PKA-RII
agonist also completely abrogated the stimulated phosphoryla-
tion of p40phox, again reproducing the effect of PGE2 (Fig.
4C). Phosphorylation of p40phox and other cytosolic subunits
of NADPHox, such as p47phox, is a prerequisite for their
translocation to membranes, where they can associate with the
catalytic core of the complex to carry out ROI generation [7].
We therefore examined the ability of the specific PKA-RII ago-
nist to inhibit membrane translocation of p40phox. After
IgG-K. pneumoniae challenge in the absence or presence of
PGE2 or the PKA-RII agonist, membrane fractions were ob-
tained by ultracentrifugation and immunoblotted for phospho-
p40phox; levels were expressed relative to that of the constitu-
tive membrane component gp91phox used as the loading con-
trol. Membrane content of activated p40phox was increased
after stimulation, with no change in gp91phox, and both PGE2
and the PKA-RII agonist blunted the increment in membrane-
BA
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Figure 3. Hierarchy of kinases controlling activation of p40phox in
AMs. AMs were treated with the PKC inhibitor rottlerin (6 M) (A
and B), the PAK inhibitor PAK18 (100 M) (C and D), or the PI3K
inhibitor LY29004 (1.5 M) (E and F) for 30 min before stimulation
with 50:1 IgG-K. pneumoniae for 15 min. Cells were lysed, and proteins
were subjected to immunoblot analysis for p-PAK (A), p-Akt (B and
C), p-ERK (D and F), and p-PKC (E). Blots were analyzed by densi-
tometry, and results are presented as the percentage of kinase phos-
phorylation in cells stimulated with IgG-K. pneumoniae alone (black in
B–F). (A) Blot from 1 experiment, with relative densitometric ratios
noted below the p-PAK band; (B–F) data represent the mean  se
from at least 3 independent experiments. #P  0.05 versus untreated
cells; *P  0.05 versus IgG-K. pneumoniae alone. p, phospho; i, inhibi-
tor, respectively.
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associated phospho-p40phox triggered by opsonized bacteria
(Fig. 4D).
It has been estimated that up to 75% of PKA type II mole-
cules are bound to cellular anchoring proteins termed AKAPs
[49], and we have previously shown that a PKA type II interac-
tion with a specific AKAP mediates PGE2 inhibition of TNF-
in rat AMs [50]. To screen for involvement of AKAPs in the
inhibitory actions of PGE2 on NADPHox activation in these
cells, we used a cell-permeable peptide, Ht31 [51], that selec-
tively disrupts PKA-RII-AKAP interactions. Neither this peptide
disruptor, at concentrations previously shown to be effective in
rat AMs [50], nor its inactive control peptide Ht31P (not
shown), prevented the decrease in H2O2 production caused by
PGE2 (Fig. 4E). Together, these results identify unanchored
PKA type II as being responsible for the inhibition of p40phox
activation caused by PGE2 and its second messenger, cAMP.
We also determined the effect of PGE2 on rat AMs chal-
lenged with unopsonized K. pneumoniae. As seen in Fig. 4F,
H2O2 production in rat AMs stimulated with unopsonized K.
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Figure 4. Unanchored PKA type II mediates
PGE2 inhibition of phosphorylation and of mem-
brane translocation of p40phox on IgG-K. pneu-
moniae stimulation. AMs were pretreated with
PKA-RI and PKA-RII specific inhibitors, respec-
tively. Rp-8-Cl-cAMPS (PKA-RI-i) and Rp-8-PIP-
cAMPS (PKA-RII-i) (A) or the specific AKAP-
PKA-RII peptide disruptor Ht31 (E) at the doses indicated for 30 min and then were treated for 10 min with 1 M PGE2 (A, C, D, E, and F) or
the PKA-RII agonist 6-MBC-cAMP (PKA-RII-a) at the indicated doses (B) or at 160 M (C, D, and F) before addition of 50:1 IgG-K. pneumoniae for
15 min (C and D) or 60 min (A, B, and E) or addition of 50:1 unopsonized K. pneumoniae for 60 min (F). Subsequently, the H2O2 concentration
in medium was determined fluorometrically (A, B, E, and F). (C) Cells were lysed, and proteins were subjected to immunoblot analysis for
p-p40phox. (D) Membrane fractions from AMs treated as indicated were prepared by ultracentrifugation, and proteins were subjected to immuno-
blot analysis for p-p40phox and gp91phox (membrane loading control) with relative densitometric ratios noted below the p-p40phox band. Data
are expressed as the percentage of the stimulated increment in H2O2 (A, B, E, and F) or of p40phox phosphorylation (C) or p40phox transloca-
tion (D) after quantification of blot band densities by densitometry in cells stimulated with IgG-K. pneumoniae alone (black in A, B, C, and E) or
stimulated with unopsonized K. pneumoniae alone (F), and represent the mean  se from at least 3 independent experiments (A, B, C, and E) or
1 blot from 1 experiment, which is representative of 2 experiments (D) or the mean of 2 independent experiments (F). #P  0.05 versus un-
treated cells; *P  0.05 versus IgG-K. pneumoniae  PGE2 (A) and IgG-K. pneumoniae alone (B, C, and E). p, phospho; a, agonist; i, inhibitor.
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had any effect on H2O2 production triggered by unopsonized
K. pneumoniae. These data suggest that the regulatory effects of
PGE2 on H2O2 production are likely to be stimulus-specific.
PI3K/Akt is the target for inhibition of p40phox
activation by PGE2 and PKA type II
PGE2 is known to inhibit the actions of various kinases [52,
53]. Thus, we determined the extent to which PGE2/PKA type
II inhibition of p40phox activation was associated with its abil-
ity to inhibit phosphorylation of the specific kinases that par-
ticipate in p40phox activation upon IgG-K. pneumoniae chal-
lenge. Neither PGE2 nor the PKA-RII agonist had any effect
on IgG-K. pneumoniae-triggered PKC phosphorylation
(Fig. 5A), and the same was true for p38 MAPK phosphoryla-
tion (not shown), PAK phosphorylation (Fig. 5B) and its
downstream target ERK (Fig. 5C). In contrast, both PGE2 and
the PKA-RII agonist completely inhibited the increase in phos-
phorylation of Akt (Fig. 5D), just as they inhibited the phos-
phorylation of p40phox (Fig. 4C). These data identify PI3K/
Akt, but not the proximal activating kinases PKC and PAK, as
a target for PKA type II action (see scheme in Fig. 7, right).
Akt1 mediates p40phox activation induced by IgG-K.
pneumoniae and is a target for inhibition by PGE2/
PKA type II
Because Akt appears to be a critical kinase playing a proximate
role in p40phox activation as well as a target for the inhibitory
actions of PGE2 and PKA, we sought to determine which Akt
isoform is involved in p40phox activation. Gene silencing us-
ing siRNA offered a strategy to not only confirm the conse-
quences of pharmacological inhibition of Akt but also to tar-
get a specific isoform of Akt. In this endeavor, we chose to
specifically focus on the Akt1 isoform [54], because of data
implicating this isoform in p40phox regulation in neutrophils
[22, 55]. In addition, the inhibitor Akti-VIII, which inhibited
both H2O2 generation (Fig. 1B) and p40phox phosphorylation
(Fig. 1D), exhibits relative specificity for Akt1 [56]. Compared
with nontargeting control siRNA, Akt1 siRNA in AMs resulted
in Akt1 protein knockdown of 40–50% (Fig. 6A), a degree
of knockdown similar to that which we have obtained previ-
ously for other proteins in primary alveolar macrophages [50].
p40phox was used as a loading control in this experiment to
exclude the possibility that the decrease in phosphorylated
p40phox shown in Fig. 6C was due to a decrease in total
p40phox expression. As also seen in Fig. 6D, expression of to-
tal ERK, PKC, and -actin was not affected by Akt1 protein
knockdown. Stimulated H2O2 production was concomitantly
decreased by 40% in cells pretreated with Akt1 siRNA (Fig.
6B). Moreover, Akt1 knockdown reduced the activation of
p40phox in AMs stimulated by IgG-K. pneumoniae by 50%
(Fig. 6C). Taken together, these data support a role for Akt1
in p40phox and NADPHox activation. As seen in Fig. 6B and
C, even baseline levels of both H2O2 generation and p40phox
activation were slightly decreased in unstimulated cells whose
Akt1 was knocked down. However, neither ERK nor PKC
phosphorylation (Fig. 6D) in IgG-K. pneumoniae-stimulated cells
was attenuated in Akt1-silenced AMs. PGE2 was still able to de-
crease H2O2 production even in Akt1-silenced cells (not shown),
probably reflecting both the incomplete nature of silencing and
its ability to also regulate activation of p47phox [28].
To evaluate a possible direct interaction between Akt1 and
its proximal target p40phox, we immunoprecipitated p40phox,
and then sought the presence of Akt1 in the immunoprecipi-
tate. As seen in Fig. 6E, coimmunoprecipitation of p40phox
and Akt1 was enhanced by stimulation with IgG-K. pneumoniae,


















































































































Figure 5. PKA type II and PGE2 inhibit p40phox activation in AMs by targeting PI3K/Akt. AMs were pretreated with 1 M PGE2 or 160 M PKA-
RII agonist 6-MBC-cAMP (PKA-RII-a) (A–D) for 10 min and then were challenged with 50:1 IgG-K. pneumoniae for 15 min. Cells were lysed, and
proteins were subjected to immunoblot analysis for total PKC and p-PKC (A), total p40phox and p-PAK (B), total ERK and p-ERK (C), and total
Akt and p-Akt (D). Blots were analyzed by densitometry, and data are expressed as the percentage of kinase phosphorylation in cells stimulated
with IgG-K. pneumoniae alone (black in A, C, and D). Data represent the mean  se from at least 3 independent experiments (A, C, and D), and
(B) is a blot from 1 experiment with relative densitometric ratios noted below the p-PAK band. #P  0.05 versus untreated cells; *P  0.05 versus
IgG-K. pneumoniae alone. p, phospho; a, agonist.
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same p40phox immunoprecipitates contained no immunode-
tectable PKC (not shown), supporting the contention that
Akt1 is directly upstream of p40phox and that PKC is not.
DISCUSSION
Among NADPHox cytosolic subunits, p40phox is now recog-
nized as more than a passive p67phox partner whose transloca-
tion is directed by p47phox [20–22]. Rather, emerging evi-
dence indicates that it too can function as a carrier of other
cytosolic subunits and as an active regulator of NADPHox [15–
22], with defects in ROI production and bacterial killing iden-
tified in p40phox/ mice [16]. However, its regulation is in-
completely understood. In particular, nothing is known about
p40phox activation in AMs or its regulation by PGE2 in any
cell type. The critical importance of these issues derives from
the clinical impact of respiratory infections globally, the role
of AMs as resident innate defenders of the distal lung, and the
ability of PGE2 to exert profound immunosuppressive actions
on leukocytes at sites of infection. Our key findings are sum-
marized in the scheme depicted in Fig. 7: we defined a kinase
cascade responsible for p40phox activation in AMs activated
via FcR ligation in which PKC is upstream of PAK, which is
upstream of class I PI3K/Akt1. In contrast, we were unable to
identify roles for PKC, ERK, p38 MAPK, or CK2 in this pro-
cess. PGE2 effects, which we have previously linked with signal-
ing via the EP2 and EP4 receptors and the cAMP effector PKA
[28], were shown here to be mediated by AKAP-unanchored
PKA type II, targeting only the most downstream of the regula-
tory kinases, class I PI3K/Akt1, culminating in p40phox inhibi-
tion.
Chessa et al. [15] reported that phosphorylation of p40phox
on Thr154 by PKC is associated with full NADPHox activation
in neutrophils. Our results define PKC as a very early partici-
pant in oxidase activation in AMs as well. On the basis of the
actions of inhibitors and siRNA as well as the kinetics of phos-
phorylation, our data suggest that PKC was upstream of class
I PI3K/Akt1 in this experimental system. PI3K has often been
identified as being very proximal in FcR signaling and up-
stream of PKC. Indeed, Toker et al. [57] suggested that the
PI3K product PIP3 could activate PKC, and in HL-60 cells
differentiated to a neutrophil-like phenotype, Yamamori et al.
[58] showed that PI3K controlled p47phox phosphorylation in
a PKC-dependent manner. In contrast, Hazeki et al. [59] re-
ported that in murine RAW264.7 macrophages, PKC regu-
lated PI3K, albeit in a negative manner. The relative impor-
tance of species, cell type, culture conditions, and stimulus in
explaining these differences remains to be defined.
We used rottlerin as a PKC inhibitor in the present studies.
Although the off target effects of this compound have been
identified [60], these have generally been observed at concen-
trations  10M, whereas we observed 90% inhibition of
H2O2 production induced by opsonized K. pneumoniae at the
low rottlerin dose of 1 M.
PAK is an effector of Rac that has been shown to participate
in NADPHox activation in neutrophils [61]. However, neither
its expression nor its participation in regulating NADPHox has











































































































































Figure 6. Akt1 is the isoform regulating p40phox activation in AMs.
AMs were pretreated for 48 h with nontargeting control (CTR) or
Akt1 (Akt1) siRNA (A–D) and then were stimulated with 50:1 IgG-K.
pneumoniae (black) for 1 h (B) or 15 min (C and D). (B) The H2O2
concentration in medium was determined fluorometrically. (A, C, and
D) Cells were lysed, and proteins were subjected to immunoblot analy-
sis for (A) Akt1, (C and D) p-p40phox, or (D) p-ERK and p-PKC. (E)
Cells were pretreated for 10 min with or without PGE2 followed by the
addition of 50:1 IgG-K. pneumoniae for 15 min. Cells were lysed, and
p40phox was immunoprecipitated using a specific Ab. Then the
p40phox immunoprecipitates were subjected to immunoblot analysis
for Akt1 and p40phox. Data are expressed as the relative percentage
to the following groups: (A) nontargeting control siRNA (CTR),
(B–D) IgG-K. pneumoniae-stimulated cells pretreated with siRNA CTR,
or (E) IgG-K. pneumoniae-stimulated cells. Data represent the mean 
se from at least 3 independent experiments (A–D) or a representative
blot from 2 experiments (E); in the latter, relative densitometric ratios
are noted below the Akt1 band. #P  0.05 versus unstimulated cells
pretreated with siRNA CTR; *P  0.05 versus unstimulated (A) or
IgG-K. pneumoniae-stimulated (B and C) cells pretreated with siRNA
CTR. p, phospho; IP, immunoprecipitation; WB, Western blot.
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pneumoniae-stimulated AMs reveal that PAK is activated after
PKC and identify it as being necessary for Akt1 activation,
ROI production, and p40phox activation. PAK has been sug-
gested to be activated downstream of PI3K [62], but our inhib-
itor data once again place PAK upstream of class I PI3K/Akt1
in this experimental system and upstream of ERK. Indeed, the
ERK kinase MEK-1 has been reported to be a direct substrate
of PAK [63], possibly explaining why ERK activation is de-
layed. Although PAK exists as many distinct isoforms, it is
likely that PAK2 is the isoform involved in regulating p40phox
activation in rat AMs. First, the total PAK Ab used is relatively
specific for PAK2, suggesting that this isoform is present in
AMs. Second, although the anti-phospho-PAK Ab used herein
recognizes multiple phosphorylated isoforms, the molecular
weight of the single band appearing on our Western blots is
consistent only with PAK2. Third, although PAK2 has a ubiqui-
tous tissue distribution, PAK1 is highly expressed only in brain,
muscle, and spleen [64]. The possibility that Rac participates
in PAK activation in this system requires further investigation.
Data on the kinetics of Akt activation, on the effects of in-
hibitors of both PI3K and Akt as well as silencing of Akt1, and
on its coimmunoprecipitation with p40phox place the class I
PI3K/Akt1 axis proximal to activation of p40phox itself. In
neutrophil-like cells, Akt has been suggested to play a major
role in membrane recruitment of p47phox and p67phox on
N-formyl-methionyl-leucyl-phenylalanine stimulation [14, 65],
and it has been reported to phosphorylate p47phox in vivo
[14] in neutrophils. Thr154, the phosphorylation site on
p40phox which is recognized by the phospho-Ab used, com-
prises the terminal residue of a RLRPRT sequence, which co-
incides with a consensus Akt phosphorylation motif,
RXRXXS/T. In neutrophils, Akt2/ mice produced 75% less
ROI, with Akt1 having no effect [55], and activation of
p47phox was reduced, suggesting that Akt2 regulates p47phox.
Moreover, it has been shown that platelet-activating factor in-
duced p67phox and p40phox phosphorylation and transloca-
tion in neutrophils in a manner dependent on PI3K/Akt1 but
independent of p47phox [22]. Such data highlight the poten-
tial for distinct and independent means of regulating the acti-
vation of specific cytosolic subunits of NADPHox. Understand-
ing the possible involvement of Akt2 in p40phox regulation
and the interrelationships between p40phox and p47phox acti-
vation and translocation in our model will require additional
investigation.
The PI3K product PIP3 also has the ability to bind to the
PX domain of p40phox [24]. Together with direct phosphory-
lation by Akt1, this mechanism may contribute to activation of
p40phox by the PI3K/Akt axis in AMs. The ability of multiple
subunit-selective inhibitors to inhibit ROI generation in IgG-K.
pneumoniae-stimulated AMs suggests that different catalytic sub-
units of class I PI3K have the potential to regulate p40phox,
indicating a degree of redundancy among those isoforms as
has previously been observed between p110 and p110 in
macrophages by Guillermet-Guibert et al [66].
Among MAPKs, we mainly focused on ERK because of its
well-known ability to contribute to NADPHox activation [67–
69] and to activation of various antimicrobial functions in AMs
[53, 70]. However, the present studies suggest that although
ERK is activated in AMs challenged with IgG-K. pneumoniae
and involved in H2O2 production, it does not regulate
p40phox activation. Instead, its participation in NADPHox ac-
tivation may reflect its effects on p47phox. The same pattern
of findings applied to p38 MAPK, contrasting with what has
been observed in neutrophils [22].
We have previously demonstrated that AMs express both









































Figure 7. Scheme illustrating activation of p40phox in AMs and its in-
hibition by PGE2. NADPHox is formed by a catalytic core (p22phox
and gp91phox), present at the membrane, and the cytosolic subunits
(p67phox, p40phox, p47phox, and Rac), which are recruited to the
cell membranes under cell activation. All the components studied
herein are represented in bold type. The established interactions
based on the work reported here are represented by solid lines,
whereas those that are incompletely characterized are represented by
dashed lines. p40phox phosphorylation and ROI production in IgG-K.
pneumoniae-stimulated AMs are regulated by a hierarchical cascade of
kinases. PKC is rapidly activated, and this controls the subsequent
activation of PAK and finally class I PI3K/Akt1. PAK itself activated
ERK. p38 MAPK is activated by PKC. However, MAPKs do not partici-
pate in activating p40phox. Endogenous PGE2 inhibits AM p40phox
activation via the second messenger cAMP acting via unanchored PKA
type II to inhibit the distal kinases PI3K/Akt. No effort was made to
represent the actual localization of each kinase in the cells. P, phos-
pho; AC, adenylyl cyclase.
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type II can modulate expression of specific cytokines [50]. The
current studies with PKA-R isoform-specific agonists and inhib-
itors as well as AKAP disruptor peptides identified unanchored
PKA type II as being both capable of inhibiting p40phox acti-
vation and mediating the inhibition of this process by PGE2 in
IgG-K. pneumoniae-triggered AMs. This inhibitory action ap-
peared to be directed at the class I PI3K/Akt1 axis and not at
more upstream kinases in the hierarchy controlling p40phox
activation. This is to our knowledge the first report describing
inhibition of p40phox by the PGE2/cAMP/PKA axis in macro-
phages or in any leukocyte population. The molecular basis
for the preferential role of PKA type II over PKA type I in
PGE2 inhibition of the activation of both PI3K/Akt and
p40phox is uncertain at the present time. It could reflect dif-
ferential sensitivities to cAMP of the two PKA isoforms [71–73]
or differences in their subcellular localization. Notably, both
PKA type II [71, 73] and PI3K/Akt [74, 75] have been re-
ported to be recruited to phagosomes where bacterial killing
by NADPHox occurs. This is in keeping with the report of Ri-
vard et al. [76], who showed that PKA type II localized to dy-
namic actin microspikes without participation of AKAPs. Thus,
class I PI3K/Akt1 is positioned at the junction of transduction
pathways activated by opsonized K. pneumoniae and PGE2/
cAMP/PKA.
The mechanism by which PKA type II inhibits PI3K/Akt re-
mains to be defined, but we can speculate about several possi-
bilities. First, PKA might directly phosphorylate PI3K. There is
precedent for phosphorylation by PKA of PI3K class I regula-
tory subunit p85 at Ser83, although this had activating rather
than inhibitory consequences [77], and to our knowledge an
inhibitory phosphorylation site on PI3K has not been de-
scribed. Second, it is possible that even an activating phos-
phorylation of PI3K by PKA allosterically interferes with the
subsequent activation of PDK1 or PDK2, or its direct substrate,
Akt, and there is precedent for the latter phenomenon [78].
Third, cAMP via PKA might inhibit Akt activation directly,
thereby blocking PDK recruitment to the membrane. It is un-
likely that PDK1 was involved in p40phox regulation in our
experimental system, because an inhibitor of this kinase failed
to attenuate p40phox phosphorylation levels induced by
IgG-K. pneumoniae (not shown). However a possible role for
PDK2 or mammalian target of rapamycin [79] mediating the
phosphorylation of Akt is not excluded and will need further
investigation. A final possibility is that PGE2/cAMP/PKA abro-
gates PI3K signaling by activation of phosphatases. One first
candidate was PTEN. PTEN is a dual protein/lipid phospha-
tase that opposes the actions of PI3K by dephosphorylating
PI3K-derived PIP3 to phosphatidylinositol 4,5-bisphosphate.
Indeed, we have previously reported [53] that PGE2 activates
the phosphatase activity of PTEN in AMs by dephosphorylating
it on Tyr residues. However, our data indicate that although it
may participate, PTEN is not the only phosphatase mediating
Akt inhibition because the decrease in stimulated H2O2 elic-
ited by PGE2 and PKA-RII was minimally abrogated by a PTEN
inhibitor (not shown). Alternatively, a phosphatase other than
PTEN might be activated, and in this regard, Zhang et al. [80]
have described PKA activation of SH2 (Src homology 2)-con-
taining inositol phosphatase-1.
The ability of PGE2 to inhibit the respiratory burst was evi-
dent when AMs were stimulated by IgG-K. pneumoniae but not
by unopsonized bacteria. This difference highlights the stimu-
lus specificity of oxidase regulation, but the precise differences
in activation cascades and their control by this prostanoid re-
main to be elucidated in future investigations.
In summary, our studies have defined the organization of
the kinase network that controls activation of p40phox in AMs.
In addition, we have identified a distal component of that net-
work, the class I PI3K/Akt1 axis, as the target by which PGE2
via PKA type II inhibits p40phox activation in this model. Be-
cause commonly used therapeutic agents such as glucocortico-
ids and nonsteroidal anti-inflammatory drugs inhibit the bio-
synthesis of PGE2, these findings provide relevant new insights
into the regulation of AM antimicrobial functions and lung
innate immunity.
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